CAMP4 Therapeutics (NASDAQ:CAMP) Upgraded to “Strong-Buy” at Chardan Capital

Chardan Capital upgraded shares of CAMP4 Therapeutics (NASDAQ:CAMP) to a strong-buy rating in a report issued on Wednesday,Zacks.com reports.

CAMP has been the topic of several other reports. Leerink Partners raised their price target on CAMP4 Therapeutics from $8.00 to $9.00 and gave the stock an “outperform” rating in a research report on Thursday, April 2nd. Rodman & Renshaw started coverage on CAMP4 Therapeutics in a research note on Tuesday, April 14th. They set a “buy” rating and a $7.00 price objective on the stock. Weiss Ratings downgraded CAMP4 Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Thursday, May 21st. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating on shares of CAMP4 Therapeutics in a research note on Friday, March 6th. One investment analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, CAMP4 Therapeutics presently has a consensus rating of “Moderate Buy” and an average price target of $8.25.

CAMP4 Therapeutics Stock Up 8.2%

NASDAQ:CAMP opened at $4.34 on Wednesday. CAMP4 Therapeutics has a 12-month low of $1.30 and a 12-month high of $7.75. The firm has a market capitalization of $225.38 million, a P/E ratio of -1.84 and a beta of 0.08. The stock’s fifty day simple moving average is $4.37 and its 200-day simple moving average is $4.68.

CAMP4 Therapeutics (NASDAQ:CAMP) last posted its quarterly earnings results on Thursday, May 7th. The Wireless communications provider reported ($0.32) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.21) by ($0.11). CAMP4 Therapeutics had a negative return on equity of 194.74% and a negative net margin of 2,193.72%.The company had revenue of $1.29 million during the quarter. As a group, equities research analysts expect that CAMP4 Therapeutics will post -0.82 earnings per share for the current year.

Institutional Trading of CAMP4 Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of CAMP. Vivo Capital LLC acquired a new stake in shares of CAMP4 Therapeutics in the 3rd quarter valued at about $11,765,000. Balyasny Asset Management L.P. acquired a new stake in shares of CAMP4 Therapeutics in the 4th quarter valued at about $14,938,000. Janus Henderson Group PLC raised its stake in shares of CAMP4 Therapeutics by 35.9% in the 4th quarter. Janus Henderson Group PLC now owns 6,307,636 shares of the Wireless communications provider’s stock valued at $38,807,000 after purchasing an additional 1,666,666 shares during the period. SummitTX Capital L.P. acquired a new stake in shares of CAMP4 Therapeutics in the 1st quarter valued at about $1,497,000. Finally, EcoR1 Capital LLC acquired a new stake in shares of CAMP4 Therapeutics in the 4th quarter valued at about $1,992,000.

CAMP4 Therapeutics Company Profile

CalAmp Corp., a connected intelligence company, provides leverages a data-driven solutions ecosystem to people and organizations in the United States, Europe, the Middle East, Africa, Latin America, the Asia-Pacific, and internationally. The company operates in two segments, Software & Subscription Services and Telematics Products. It provides CalAmp Telematics Cloud platform, such as cloud-based application enablement and telematics service platforms that facilitate integration of its own applications, as well as those of third parties, through open application programming interfaces; and software as a service application, as well as provides tracking and monitoring services within fleet management, supply chain integrity, and international vehicle location.